Skip to content

Heinrich, Lujan, Stansbury Welcome Over $2.2 Million in Federal Funding for Cancer, Drug Abuse and Addiction Research, and Health Centers in New Mexico

WASHINGTON - U.S. Senators Martin Heinrich (D-N.M.), Ben Ray Luján (D-N.M.), and U.S. Representative Melanie Stansbury (D-N.M.) are welcoming over $2 million in federal grants from the U.S. Department of Health and Human Services (HHS). The $2,229,543 will support cancer treatment, drug abuse and addiction research, and improvements to health centers in New Mexico. 

“This much-needed federal funding will help us in the fight to end cancer and the opioid epidemic in New Mexico,” said Heinrich. “We must continue to improve access to addiction treatment services and lifesaving care for all. This federal funding is an important part of that work, investing millions to improve the health and wellbeing of every New Mexican.”

“Families across New Mexico know the toll it takes when a loved one is diagnosed with cancer or struggles with addiction. I’m proud to welcome nearly $2.3 million to support cancer treatment and drug abuse and addiction research, in addition to supporting our health centers,” said Luján.“These investments will help New Mexicans live healthy lives and have access to high-quality care.”

“Health care research is crucial to the health and safety of our communities, and New Mexico is the proud home of some of the most innovative research hubs in the country,” said Rep. Stansbury.“Investing in cancer treatments and addiction recovery research doesn’t just contribute to the academic field—it means longer lives and more families who get to stay together. I’m grateful that HHS has recognized the need for further research into these fields, and that they would place their well-earned trust into our state’s researchers.”

HHS is awarding more than $1.2 million to the New Mexico Primary Care Association through the Health Resources and Services Administration (HRSA) division to help health centers in New Mexico improve programmatic, clinical, and financial performance and operations.

HHS is awarding a grant of more than $651,000 to the Lovelace Biomedical Research Institute through the Drug Abuse and Addiction Research Program. Specifically, this grant will fund research to improve our standing of respiratory disorder caused by Carfentanil and help to develop new knowledge and approaches related to diagnosis, treatment, and prevention.

Additionally, HHS is providing a grant of more than $374,000 to the University of New Mexico through the National Cancer Institute to study and treat ovarian cancer.